260. シトステロール血症 [臨床試験数:12,薬物数:11(DrugBank:4),標的遺伝子数:1,標的パスウェイ数:1]
Searched query = "Sitosterolemia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01948648 | February 6, 2018 | 19 November 2018 | Effects of Fish Oil and Colesevelam | Effects of Fish Oil, Colesevelam and Combination Therapy on Sterol Metabolism in Sitosterolemia | Sitosterolemia | Drug: Colesevelam;Dietary Supplement: Fish Oil;Drug: Combination of fish oil and colesevelam | University of Manitoba | Recruiting | 8 Years | N/A | All | 16 | N/A | Canada | |
2 | NCT01584206 | April 2012 | 11 April 2016 | Sitosterolemia Metabolism | Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe | Sitosterolemia | Drug: Ezetimibe | University of Manitoba | Not recruiting | 16 Years | 99 Years | Both | 8 | N/A | Canada | |
3 | NCT00531128 | September 10, 2007 | 11 June 2018 | The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol | A Nutrigenomics Intervention for the Study of the Role of Dietary Sitosterol on Lipid, Glucose and Energy Metabolism | Sitosterolemia | Behavioral: High/Low Sitosterol | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 18 Years | N/A | All | 14 | N/A | United States | |
4 | NCT00704444 | June 2007 | 9 March 2015 | A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244) | Designated Drug Use Investigation (12 Weeks) of Zetia 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy | Hypercholesterolemia;Familial Hypercholesterolemia;Homozygous Sitosterolemia | Drug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s) | Merck Sharp & Dohme Corp. | Bayer | Not recruiting | N/A | N/A | Both | 11332 | N/A | |
5 | NCT00705211 | June 2007 | 9 March 2015 | A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245) | Designated Drug Use Investigation (Long-Term Administration) of Zetia 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy | Hypercholesterolemia;Familial Hypercholesterolemia;Homozygous Sitosterolemia | Drug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s) | Merck Sharp & Dohme Corp. | Bayer | Not recruiting | N/A | N/A | Both | 1794 | N/A | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | EUCTR2004-001580-22-DE | 21/12/2004 | 10 February 2014 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study | Homozygous Sitosterolemia | Trade Name: Ezetrol Product Name: Ezetrol Product Code: MK-0653 Pharmaceutical Form: Tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10, 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | MSD SHARP & DOHME GMBH | Not Recruiting | Female: yes Male: yes | 30 | Germany;United Kingdom | ||||
7 | NCT00099996 | December 2004 | 19 February 2015 | Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia | A Study to Assess Adding Ezetimibe 30 mg to Ongoing Treatment With Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia | Heart Diseases;Metabolism, Inborn Errors | Drug: SCH-58235;Drug: Ezetimibe | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | N/A | Both | 3 | Phase 3 | United States | |
8 | NCT00092898 | October 2004 | 16 December 2017 | An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to An Ongoing Regimen of Ezetimibe 10 mg in Patients Homozygous Sitosterolemia | Lipid Metabolism, Inborn Errors;Heart Disease | Drug: MK0653, ezetimibe;Drug: Comparator: placebo | Merck Sharp & Dohme Corp. | Not recruiting | 18 Years | 85 Years | All | 30 | Phase 3 | United States | |
9 | NCT00092833 | July 2002 | 16 December 2017 | Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED) | An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia | Hypercholesterolemia, Familial;Lipid Metabolism, Inborn Errors | Drug: Comparator: ezetimibe | Merck Sharp & Dohme Corp. | Not recruiting | 8 Years | N/A | All | 49 | Phase 3 | United States | |
10 | NCT00045812 | March 2001 | 19 February 2015 | SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygous Sitosterolemia | Lipoidosis | Drug: SCH-58235 | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | N/A | Both | 5 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT00092807 | February 12, 2001 | 16 December 2017 | Sitosterolemia Extension Study (0653-003)(COMPLETED) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension | Lipid Metabolism, Inborn Errors;Heart Disease | Drug: MK0653, ezetimibe;Drug: Comparator: placebo | Merck Sharp & Dohme Corp. | Not recruiting | 10 Years | N/A | All | 37 | Phase 3 | United States | |
12 | NCT00092820 | February 12, 2001 | 16 December 2017 | Sitosterolemia Extension Study (0653-004)(COMPLETED) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia | Lipid Metabolism, Inborn Errors;Heart Disease | Drug: MK0653, ezetimibe;Drug: Comparator: placebo | Merck Sharp & Dohme Corp. | Not recruiting | 10 Years | N/A | All | 58 | Phase 3 |